AVCTF (Avacta Group) Risk Assessment


AVCTF Avacta Group PLC AVCTF
13 GF Score
Price $1.00
GF Value $0.67
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avacta Group Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Avacta Group is: No Data: Cannot be evaluated.

Avacta Group  (OTCPK:AVCTF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Avacta Group Risk Assessment Related Terms

AVCTF vs VRTX, REGN, ALNY: Risk Assessment Comparison

For the Biotechnology subindustry, Avacta Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avacta Group Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Avacta Group's Risk Assessment falls into.


AVCTF
13GF Score
Avacta Group PLC AVCTF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Avacta Group (AVCTF) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of $1.00 is trading 49.3% above its estimated GF Value™ of $0.67. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for AVCTF:

  • Risk Assessment:
  • GF Value™: $0.67 vs. price of $1.00 (49.3% above fair value)
  • GF Score™: 13/100 with 8 warning signs

No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avacta Group Business Description

Other Exchanges AVCT:UKRTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score

Get the complete analysis for AVCTF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.67
GF Value